B
Boris Bahoric
Researcher at McGill University
Publications - 56
Citations - 655
Boris Bahoric is an academic researcher from McGill University. The author has contributed to research in topics: Prostate cancer & Androgen deprivation therapy. The author has an hindex of 12, co-authored 43 publications receiving 491 citations. Previous affiliations of Boris Bahoric include McGill University Health Centre & Jewish General Hospital.
Papers
More filters
Journal ArticleDOI
Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial.
Abdenour Nabid,Nathalie Carrier,André-Guy Martin,Jean Paul Bahary,Céline Lemaire,Sylvie Vass,Boris Bahoric,Robert Archambault,François Vincent,Redouane Bettahar,Marie Duclos,Marie Pierre Garant,Luis Souhami +12 more
TL;DR: Outcomes from high-risk prostate cancer patients treated with radiotherapy and either 36 or 18 mo of androgen deprivation therapy showed no difference in survival between the two groups, with the 18-mo group experiencing a better quality of life.
Journal ArticleDOI
Predicting Gleason Score of Prostate Cancer Patients Using Radiomic Analysis.
TL;DR: The results suggest that the radiomic features can be used as a non-invasive biomarker to predict the Gleason score of the PCa patients.
Journal ArticleDOI
Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype
Xingrao Wu,Ayesha Baig,Goulnar Kasymjanova,Kamran Kafi,Christina Holcroft,Hind Mekouar,Annie Carbonneau,Boris Bahoric,Khalil Sultanem,Thierry Muanza +9 more
TL;DR: Of the four subtypes, the LA subtype tends to have the best prognosis, fairly high survival, and low recurrent or metastases rates, and a statistically significant association between survival and molecular subtypes in an univariate analysis is demonstrated.
Journal ArticleDOI
Long-term results of high-dose-rate brachytherapy in the primary treatment of medically inoperable stage I-II endometrial carcinoma.
TL;DR: Medically inoperable Stage I endometrial carcinoma may be safely and effectively treated with HDRB as the primary therapy, and results are equivalent to that of surgery in selected Stage I patients.
Journal ArticleDOI
Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy.
Té Vuong,Neil Kopek,Thierry Ducruet,Lorraine Portelance,Sergio Faria,Boris Bahoric,Slobodan Devic +6 more
TL;DR: The use of 3D-CRT allows patients with anal canal cancer to complete radiation and chemotherapy without interruption for toxicity, with significant improvements in LC, FFR, and OS.